Dr Reddys launches Methylprednisolone Sodium Succinate for Injection in US market

9 Apr 2022 , 01:35 AM

Dr Reddys Laboratories announced the launch of Methylprednisolone Sodium Succinate for Injection USP the generic equivalent of SOLU-MEDROL methylprednisolone sodium succinate for injection USP in the US Market approved by the US Food and Drug Administration USFDA The SOLU-MEDROL brand and generic had US sales of approximately $144 million MAT for the most recent twelve months ending in February 2022 according to IQVIA Health Dr Reddys Methylprednisolone Sodium Succinate for Injection USP is supplied in 40 mgvial125 mgvial single-dose vials each carton containing 25 vials; 500 mg and 1 gm multi-dose vial each carton containing 1 vial